People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allocure Inc | — | Biotechnology | Series B | $50.5M | $1.1B | 2009 |
John Wirthlin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Wirthlin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mette Kirstine Agger | 1 | 6 |
| Lutz Giebel | 1 | 6 |
| Christof Westenfelder | 1 | 2 |
| Robert M Brenner | 1 | 1 |
| Thomas B. Dyrberg | 1 | 1 |
| Scott Kirstine Canute | 1 | 1 |
| David Kirstine Guyer | 1 | 1 |
| Lutz B. Giebel | 1 | 1 |
| Kevin J. Heyeck | 1 | 1 |
| George M. Eldridge | 1 | 1 |
| Thomas Dryberg | 1 | 1 |
| John B. Wirthlin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.